RNA splicing is a key process that shapes how genes are expressed and can generate novel antigens that influence tumour–immune interactions. In this project, we are investigating how alterations in RNA splicing affect tumour immunogenicity and contribute to both response and resistance to immunotherapy. By mapping splicing events and their impact on immune recognition, we aim to uncover new biomarkers of treatment response and identify therapeutic opportunities to overcome resistance.